Methods of inhibiting primary endometrial hyperplasia

Details Methods of inhibiting primary endometrial hyperplasia Methods of inhibiting primary endometrial hyperplasia

A - Human Necessities

61

K

A61K 31/38 (2006.01) A61K 31/381 (2006.01) A61K 31/40 (2006.01) A61K 31/4025 (2006.01) A61K 31/445 (2006.01) A61K 31/4535 (2006.01) A61K 31/55 (2006.01)

Patent

CA 2198120

A method of inhibiting primary endometrial hyperplasia comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a) or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.

Le procédé enrayant l'hyperplasie endométriale primaire de la présente invention consiste à administrer à un être humain le nécessitant une quantité suffisante d'un composant représenté par la formule générale (I) ou de l'un de ses sels ou solvates pharmaceutiquement acceptables. Dans cette formule générale R?1¿ et R?3¿ sont indépendamment hydrogène, -CH¿3?, -C(=O)-C¿1?-C¿6? alkyle, ou -C(=O)-Ar, où Ar est un phényle éventuellement substitué. R?2¿ appartient au groupe formé par pyrrolidine, hexaméthylèneimino et pipéridino; ou un sel ou solvate pharmaceutiquement acceptable du composé.

Affiliated with

Also associated with

Rating

Methods of inhibiting primary endometrial hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting primary endometrial hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting primary endometrial hyperplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1953952